The Absolute Risk of Cervical Abnormalities in High-risk Human Papillomavirus–Positive, Cytologically Normal Women Over a 10-Year Period
- 1 November 2006
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 66 (21), 10630-10636
- https://doi.org/10.1158/0008-5472.can-06-1057
Abstract
In spite of the success of cervical cytology as a cancer-screening tool, it has important limitations, and human papillomavirus (HPV) testing may be valuable in future screening. The majority of women in screened populations, who test HPV positive, will have a concurrent normal smear, and we need more information about the risk for subsequent high-grade cervical lesions in these women. We examined 8,656 younger women (22–32 years old) and 1,578 older women (40–50 years old) who were followed for development of cervical neoplasia (cytology and/or histology) through the Danish Pathology Data Bank. We estimated the proportion of women developing cervical lesions of different types before a given time point as a function of time. Among women with normal cytology and positive high-risk Hybrid Capture 2 (HC2) test, 17.7% and 24.5% of younger and older women, respectively, had a subsequent abnormal Pap smear within 5 years. The risk of CIN3 or cancer within 10 years among younger women with positive HC2 test was 13.6% (10.9–16.2) and 21.2% (2.7–36.1) among older women. An analysis among younger women also being HC2-positive 2 years before baseline showed a subsequent 10-year risk of ≥CIN3 of 18% (14.6–21.5). Among older women where HPV may be added to general screening, the estimated absolute risk of ≥CIN3 in HC2-positive women was more than 20% within 10 years. These results indicate that even a single positive HPV test in cytologically negative women is substantially predictive of high-grade CIN and suggest that HC2 testing can help stratify women into different risk categories. (Cancer Res 2006; 66(21): 10630-6)Keywords
This publication has 14 references indexed in Scilit:
- The Elevated 10-Year Risk of Cervical Precancer and Cancer in Women With Human Papillomavirus (HPV) Type 16 or 18 and the Possible Utility of Type-Specific HPV Testing in Clinical PracticeJNCI Journal of the National Cancer Institute, 2005
- The carcinogenicity of human papillomavirus types reflects viral evolutionVirology, 2005
- Chapter 12: Human Papillomavirus TechnologiesJNCI Monographs, 2003
- Absolute risk of a subsequent abnormal pap among oncogenic human papillomavirus DNA‐positive, cytologically negative womenCancer, 2002
- Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up studyBMJ, 2002
- Persistent Human Papillomavirus Infection as a Predictor of Cervical Intraepithelial NeoplasiaJAMA, 2001
- Risks for Incident Human Papillomavirus Infection and Low-Grade Squamous Intraepithelial Lesion Development in Young FemalesJAMA, 2001
- Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort studyThe Lancet, 2001
- Accuracy of the Papanicolaou Test in Screening for and Follow-up of Cervical Cytologic AbnormalitiesAnnals of Internal Medicine, 2000
- Human papillomavirus is a necessary cause of invasive cervical cancer worldwideThe Journal of Pathology, 1999